Premier Alternatives

Eikonizo Therapeutics

Cambridge, MA · Founded 2017 · Privately Held (backing)

Developer of brain-penetrant and peripherally-restricted small molecules designed to slow or modify the progression of neurodegenerative and cardiorenal diseases. Eikonizo Therapeutics is based in Cambridge, MA and was founded in 2017. It was valued at $54 million at its later-stage round in Dec 2023, the last priced event on record. It has raised $46.1 million across 2 recorded rounds; the latest was a $371,352 seed round in May 2018.

PMV mark · valuation
$54.0M
Oct 2026
Priced at
its later-stage round
Dec 2023
Total raised
$46.1M
Last round
Seed Round
May 2018

Eikonizo Therapeutics key facts

as of Oct 2026
  • Developer of brain-penetrant and peripherally-restricted small molecules designed to slow or modify the progression of neurodegenerative and cardiorenal diseases.
  • Eikonizo Therapeutics is valued at approximately $54.0M as of Oct 2026, set at its later-stage round, Dec 2023; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $46.1M across 2 recorded rounds; the latest was Seed Round ($371K) in May 2018.
  • Notable investors include National Institutes of Health, F-Prime Capital, Johnson & Johnson Innovation - JLABS, Mission BioCapital, Alzheimers Drug Discovery Foundation — 8 tracked in total.
  • Eikonizo Therapeutics has filed 2 Form Ds with the SEC, most recently May 2018 ($371K sold to 1 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$54.0M

Valued at $54.0M at its later-stage round, Dec 2023. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Eikonizo Therapeutics with a free account
  • ·Watch Eikonizo Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Eikonizo Therapeutics funding rounds

2 rounds
May 2018Seed Round$371KSEC filing▮
Mar 2018Seed Round$2.0MSEC filing▮
Full funding history →

Eikonizo Therapeutics valuation

Eikonizo Therapeutics was valued at $54 million at its later-stage round in Dec 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Eikonizo Therapeutics raised?

Eikonizo Therapeutics has raised $46.1 million in total; 2 of its rounds are on record. The largest on record was a $371,352 seed round in May 2018.

Eikonizo Therapeutics has filed 2 Form Ds with the SEC, most recently in May 2018 ($371,352 sold to 1 investor).

Eikonizo Therapeutics investors

8 investors are on record for Eikonizo Therapeutics, including National Institutes of Health, F-Prime Capital, Johnson & Johnson Innovation - JLABS and Mission BioCapital. The seed round in May 2018 drew 1 investor.

About Eikonizo Therapeutics

Developer of brain-penetrant and peripherally-restricted small molecules designed to slow or modify the progression of neurodegenerative and cardiorenal diseases. The company offers selective HDAC6 inhibitors, dual-action intracellular transport and proteostasis modulation, and mitigation of protein aggregation, enabling patients and healthcare providers to improve cellular health, preserve nerve function, and potentially delay disease onset.

Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2017
Employees
10
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.